Oritavancin, known for its convenient 1-time dosing, is effective against skin and soft tissue infections, particularly involving serious gram-positive bacteria. Investigators at JMI Laboratories sought to determine whether oritavancin was also efficacious against a contemporary collection of Staphylococcus aureus
isolates causing serious infections in hospitalized patients in Europe.
In a poster presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019
), the research team detailed their study, involving a total of 1232 S aureus
isolates collected from invasive infections at 33 medical centers in 13 European and adjacent countries and regions in 2017-2018. Infections included bloodstream infections (BSIs; 77.8% of all isolates), followed by pneumonia (17.2%), bone and joint infections (BJIs; 3.1%), and intra-abdominal infections (IAIs; 1.9%).
Using Clinical and Laboratory Standards Institute and EUCAST breakpoints for susceptibility, investigators demonstrated that oritavancin (MIC50
, 0.03/0.06 mg/L) inhibited all S aureus
isolates at ≤0.12 mg/L (susceptible breakpoint). Against methicillin-resistant S aureus
(MRSA) and methicillin-susceptible S aureus
(MSSA), oritavancin yielded similar MIC50
(0.03 mg/L) and MIC90
(0.03-0.06 mg/L) results regardless of infection type.
The MIC values remained at 0.03/0.03-0.06 mg/L despite the rates of MRSA varying greatly among European countries (0%-46.6%).
“MSSA isolates showed high overall susceptibility rates (≥98.0%) to oritavancin, vancomycin, teicoplanin, linezolid, and clindamycin,” investigators reported. “These agents, except clindamycin, remained active against MRSA isolates, regardless of infection type; however, oritavancin had MIC50
results 16- to 32-fold lower than vancomycin, teicoplanin, and linezolid.”
In all, 3 S aureus
isolates displayed teicoplanin resistance (MIC >2 mg/L), 2 showed vancomycin MIC results of 2 mg/L, and all 3 were inhibited by oritavancin MIC values between 0.03 and 0.12 mg/L.
“The lipoglycopeptide oritavancin remained potent against S aureus
, including MRSA, causing serious infections in European medical centers and surrounding regions,” investigators concluded. “Its prolonged half-life and high potency may support oritavancin as a good option for treating serious S aureus
The study, “Oritavancin Activity Against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018)
,” was presented in a poster session on Monday, April 15, 2019, at ECCMID 2019 in Amsterdam, the Netherlands.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.